Leaked Data Boost J&J and Legend’s CAR-T Carvykti But Manufacturing Issues Remain
Risk Of Progression Or Death Cut By 74%
An accidental peek at data suggests Carvykti can outperform Bristol Myers Squibb’s rival CAR-T therapy Abecma, if it can prove a survival benefit and overcome manufacturing limitations that are hampering both products.
You may also be interested in...
Bristol Myers and 2seventy bio are hoping Abecma will be the first CAR-T therapy for earlier lines of multiple myeloma, but an advisory committee meeting will hold up the sBLA.
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.
BMS’s myeloma CAR-T, Abecma, has faced manufacturing backlogs, like its rival, J&J and Legend Biotech’s Carvykti, with viral vector shortages playing a significant role.